Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
- 30 Downloads
By monitoring serum concentrations of infliximab (IFX) and adalimumab (ADL) and levels of their antibodies in patients with inflammatory diseases, clinicians can adjust dose and increase safety and effectiveness of treatment. The aim was to develop and validate in-house enzyme-linked immunosorbent assays (ELISAs) for IFX and ADL, together with anti-IFX and anti-ADL ELISAs for routine detection and further analysis with acid dissociation of immune complexes. Furthermore, the objectives were to compare in-house assays with commercial ELISAs and reporter gene assays (RGAs) and to determine cross-reactivity between original Remicade®/Remsima™ and their antibodies. In-house ELISAs were validated (imprecision, accuracy among other criteria) and compared with commercial apDia ELISAs and RGAs. Correlation coefficients, intraclass correlation coefficients, agreement, and bias were calculated. All in-house ELISAs gave precise and repeatable results. The immune complexes between IFX and anti-IFX were found in 3% of samples, while complexes between ADL and anti-ADL were found in 14% of samples. Significant correlations were found between in-house and apDia ELISAs and RGA for IFX, ADL, anti-IFX, and anti-ADL results. Remicade®, Remsima™, and their antibodies could be accurately measured with either apDia or in-house IFX and anti-IFX ELISAs. Accurate and precise in-house ELISAs, highly comparable with commercial ELISAs and RGAs, were developed and validated for routine analysis of samples of patients treated with IFX (Remicade® or Remsima™) or ADL providing substantial cost benefit. Complex dissociation identified samples with anti-IFX-IFX (3%) and anti-ADL-ADL (14%) complexes indicating the benefit of adding acid dissociation to therapeutic drug monitoring of IFX and ADL.
KeywordsInfliximab Adalimumab Anti-drug antibodies ELISA Reporter gene assay Biosimilars
The authors would like to thank all the staff in the Department of Rheumatology and the Immunology Laboratory, who helped collect and process the patient samples.
The authors received financial support from the Slovenian Research Agency for funding the National Research Program “Systemic Autoimmune Diseases” (No. P3-0314).
All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Compliance with ethical standards
This study was conducted as part of the National Research Program (No. P3-0314) and has been approved by the Slovenian Ethical Committee (#99/04/15 and #38/01/16). It has therefore been performed in accordance with the ethical standards laid down in 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all individuals included in this study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations. J Crohn's Colitis. 2017;11(2):135–49. https://doi.org/10.1093/ecco-jcc/jjw169.
- 9.Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030. https://doi.org/10.1016/j.crohns.2012.09.002.CrossRefPubMedGoogle Scholar
- 10.Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976–86. https://doi.org/10.1136/ard.2009.126573.CrossRefPubMedGoogle Scholar
- 13.Yoo DH, Oh C, Hong S, Park W. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015;11(Suppl 1):S15–24. https://doi.org/10.1586/1744666x.2015.1090314.CrossRefPubMedGoogle Scholar
- 14.Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of results. Clin Gastroenterol Hepatol. 2016;14(9):1302–9. https://doi.org/10.1016/j.cgh.2016.05.010.CrossRefPubMedGoogle Scholar
- 16.Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6. https://doi.org/10.3389/fimmu.2015.00109.
- 17.van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8. https://doi.org/10.1016/j.jim.2010.09.005.CrossRefPubMedGoogle Scholar
- 20.Ogric M, Tercelj M, Praprotnik S, Tomsic M, Bozic B, Sodin-Semrl S, et al. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunol Res. 2017;65(1):172–85. https://doi.org/10.1007/s12026-016-8824-8.CrossRefPubMedGoogle Scholar
- 21.Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, et al. Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients. Ther Drug Monit. 2017;39(4):316–21. https://doi.org/10.1097/ftd.0000000000000419.CrossRefPubMedGoogle Scholar
- 22.Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–88. https://doi.org/10.1016/j.jim.2012.06.002.CrossRefPubMedGoogle Scholar
- 23.Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373(1–2):229–39. https://doi.org/10.1016/j.jim.2011.08.022.CrossRefPubMedGoogle Scholar
- 25.Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37(4):479–85. https://doi.org/10.1097/ftd.0000000000000162.CrossRefPubMedGoogle Scholar
- 26.Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–7. https://doi.org/10.1016/j.jpba.2016.03.029.CrossRefPubMedGoogle Scholar
- 27.CLSI (2014) Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition. CLSI document EP05-A3. Clinical and Laboratory Standards Insitute,Google Scholar
- 28.Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(9):2172–7. https://doi.org/10.1097/mib.0000000000000434.CrossRefPubMedGoogle Scholar
- 29.Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;36(5):669–73. https://doi.org/10.1097/ftd.0000000000000074.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.e1323. https://doi.org/10.1053/j.gastro.2015.02.031.CrossRefPubMedGoogle Scholar
- 31.Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–53. https://doi.org/10.1111/apt.14368.CrossRefPubMedGoogle Scholar
- 34.Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207. https://doi.org/10.1371/journal.pone.0175207.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969–75. https://doi.org/10.1097/mib.0000000000000709.CrossRefPubMedGoogle Scholar
- 38.Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38. https://doi.org/10.1016/j.jim.2015.01.007.CrossRefPubMedGoogle Scholar